GO:0019900 kinase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019900 (kinase binding) is a molecular function defined as binding to a kinase, any enzyme that catalyzes the transfer of a phosphate group.
• Kinase binding underlies the assembly of signaling complexes and is a prerequisite for substrate phosphorylation and inhibitor action [1, 3].
• Small-molecule kinase inhibitors frequently achieve selectivity by engaging binding pockets that overlap with protein-protein interaction surfaces [1, 4, 6].
• Pseudokinases retain nucleotide-binding capability and can act as kinase-binding scaffolds even when catalytically impaired.
• FDA-approved kinase inhibitors exemplify how kinase binding can be exploited therapeutically across oncology and beyond.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test the causal role of kinase-binding interfaces.
Description
Kinase binding (GO:0019900) is a molecular function that describes the physical interaction between a protein and a kinase, where a kinase is any enzyme that catalyzes the transfer of a phosphate group. This term captures the binding event itself, independent of whether the bound kinase subsequently phosphorylates a substrate. In cellular signaling, kinase binding is a pervasive mechanism for assembling complexes, localizing enzymes, and regulating catalytic output [1, 3]. The quantitative analysis of kinase inhibitor selectivity has shown that small molecules frequently compete with or allosterically modulate kinase-binding interfaces, underscoring the functional importance of these contacts. Because kinases are central to nearly every signaling pathway, understanding kinase binding is essential for interpreting disease mechanisms and for designing selective therapeutics [3, 8]. Researchers studying kinase binding need robust experimental systems to distinguish binding events from downstream phosphorylation and to determine which interfaces are causal in a given phenotype.
kinase binding At A Glance
| GO ID | GO:0019900 |
|---|---|
| GO term | kinase binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a kinase enzyme, enabling complex formation and regulation of phosphorylation-dependent signaling |
| Definition source | QuickGO definition: Binding to a kinase, any enzyme that catalyzes the transfer of a phosphate group. |
| Related activity | Kinase inhibitor selectivity and pseudokinase scaffolding [1, 7] |
| Therapeutic relevance | FDA-approved small-molecule kinase inhibitors target kinase-binding pockets |
What Is GO:0019900?
GO:0019900 (kinase binding) is defined as binding to a kinase, any enzyme that catalyzes the transfer of a phosphate group. It is a molecular_function term in the Gene Ontology. The definition emphasizes the binding interaction rather than the catalytic activity of the kinase; thus, a protein that binds a catalytically inactive pseudokinase can still be annotated with this term. The term does not specify the chemical nature of the binding interface, the affinity, or the functional consequence, all of which must be determined experimentally [1, 3].
Why Is kinase binding Important in Cell Biology?
Kinase binding is important because it governs the assembly, localization, and activity of signaling complexes that control cell proliferation, differentiation, and survival. Small-molecule kinase inhibitors, many of which are FDA-approved, achieve their effects by binding to kinase domains and competing with or modulating protein-protein interactions [1, 8]. The selectivity of these inhibitors depends on the precise structural features of the kinase-binding pocket, as demonstrated by quantitative analyses of inhibitor selectivity across the kinome. Moreover, pseudokinases can bind nucleotides and partner proteins, acting as scaffolds that modulate signaling without catalyzing phosphorylation. Consequently, kinase binding is a central node for both mechanistic research and therapeutic intervention [3, 6].
• Kinase binding is a prerequisite for many phosphorylation-dependent signaling events.
• It determines the selectivity and efficacy of small-molecule kinase inhibitors [1, 8].
• Pseudokinases can function as kinase-binding scaffolds, expanding the regulatory repertoire.
• Kinase binding interfaces are emerging targets for covalent and allosteric modulators [3, 4].
• Dysregulated kinase binding contributes to cancer, inflammatory diseases, and metabolic disorders.
• Understanding kinase binding aids in predicting drug resistance mutations.
• It enables the design of conformation-tunable inhibitors with improved selectivity.
• Kinase binding is essential for the mechanism of action of FDA-approved drugs such as imatinib and erlotinib.
• It provides a framework for interpreting genome-wide association studies and somatic mutations.
• Experimental models of kinase binding are critical for target validation and drug discovery.
Molecular Mechanism of kinase binding
Kinase domain architecture and binding pockets
In simple terms: Kinases have a conserved pocket where they bind ATP and substrates, and other proteins can bind to this same region.
The kinase domain is a bilobed structure with a catalytic cleft that binds ATP and peptide substrates. The DFG motif and the adjacent DFG-1 residue form part of the binding pocket that can be exploited for selective inhibitor design. Quantitative analysis of kinase inhibitor selectivity has revealed that small molecules occupy distinct subpockets within this cleft, and the shape and flexibility of these pockets determine binding affinity and selectivity. Conformation-tunable inhibitors can adapt to different kinase conformations, further highlighting the dynamic nature of the binding pocket.
Nucleotide binding and pseudokinase scaffolds
In simple terms: Even kinases that cannot catalyze phosphorylation can still bind nucleotides and partner proteins.
Pseudokinases are kinase-like proteins that have lost catalytic activity but often retain the ability to bind nucleotides. Nucleotide-binding mechanisms in pseudokinases involve conserved motifs that coordinate ATP or ADP, and these binding events can stabilize the pseudokinase and mediate protein-protein interactions. Thus, pseudokinases can function as kinase-binding scaffolds, recruiting active kinases or substrates into signaling complexes. This expands the functional scope of GO:0019900 beyond catalytically active kinases.
Allosteric and orthosteric modulation of kinase binding
In simple terms: Drugs can block kinase binding by occupying the same pocket as the natural partner or by changing the kinase shape.
Small-molecule kinase inhibitors can act as orthosteric competitors that occupy the ATP-binding site, or as allosteric modulators that bind outside the active site and alter kinase conformation. The development of conformation-tunable ATP-competitive inhibitors demonstrates that binding can be tuned to specific kinase states. DFG-1 binding represents a new residue for developing selective kinase inhibitors, illustrating how targeting distinct binding subpockets can improve selectivity. These principles are directly relevant to understanding how kinase binding is regulated and how it can be pharmacologically manipulated.
Kinase downregulation and induced degradation
In simple terms: Some drugs bind kinases and cause them to be degraded rather than just inhibited.
Small-molecule kinase downregulators are compounds that bind kinases and induce their degradation, often by recruiting E3 ubiquitin ligases. This approach exploits kinase binding to achieve selective elimination of the target protein rather than mere inhibition of its catalytic activity. Such downregulators expand the therapeutic strategies that rely on kinase binding and highlight the importance of characterizing binding interfaces for drug development.
NAD+ kinase as a paradigm of kinase binding
In simple terms: NAD+ kinase is an enzyme that binds NAD+ and phosphorylates it, and its binding properties have been studied for decades.
NAD+ kinase catalyzes the phosphorylation of NAD+ to NADP+ and is a classic example of a kinase whose binding interactions have been reviewed extensively. Although the review predates modern structural biology, it established foundational concepts about kinase-substrate binding and regulation. Modern studies of kinase binding often use NAD+ kinase as a model for understanding nucleotide recognition and catalysis.
Key Genes Involved in GO:0019900 kinase binding
The following genes encode kinases and kinase-binding proteins that are frequently studied in the context of GO:0019900, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABL1 | Non-receptor tyrosine kinase; binds ATP and substrates | Target of imatinib; kinase binding mutations cause resistance |
| EGFR | Receptor tyrosine kinase; binds ATP and downstream partners | FDA-approved inhibitors target its kinase domain |
| BRAF | Serine/threonine kinase in MAPK pathway | Vemurafenib binds mutant BRAF; kinase binding determines selectivity |
| ALK | Receptor tyrosine kinase; binds ATP and signaling proteins | Crizotinib and other inhibitors block kinase binding |
| JAK2 | Tyrosine kinase in cytokine signaling | Ruxolitinib binds JAK2 kinase domain |
| SRC | Non-receptor tyrosine kinase | Model for studying kinase binding and inhibitor design |
| CDK2 | Cyclin-dependent kinase; binds cyclins and ATP | Kinase binding is essential for cell cycle progression |
| MAPK1 | Extracellular signal-regulated kinase 2 | Binds MEK and substrates; kinase binding regulates signaling |
| PINK1 | Serine/threonine kinase with pseudokinase-like features | Binds substrates and regulates mitophagy |
| TRIB1 | Pseudokinase that binds COP1 and other proteins | Scaffold function independent of catalysis |
| STRAD | Pseudokinase that binds and activates LKB1 | Kinase binding is required for LKB1 function |
| FERONIA | Receptor kinase that binds RALF peptides | Phase separation mediates kinase binding and signaling |
| NADK | NAD+ kinase | Classic kinase binding and catalysis model |
| KSR1 | Kinase suppressor of Ras; pseudokinase scaffold | Binds RAF and MEK to facilitate signaling |
| ILK | Integrin-linked kinase; binds integrins and adaptors | Kinase binding regulates cell adhesion |
| PDK1 | 3-phosphoinositide-dependent kinase-1 | Binds substrates and regulates AGC kinases |
How Is kinase binding Regulated?
Kinase binding is regulated at multiple levels. The conformational state of the kinase domain, influenced by phosphorylation, nucleotide occupancy, and interacting partners, determines whether a binding event occurs [1, 4]. Pseudokinases can bind nucleotides and act as scaffolds, and their binding properties are modulated by conserved motifs. Small-molecule inhibitors can compete with or allosterically modulate kinase binding, and downregulators can induce degradation by recruiting E3 ligases. Additionally, phase separation of receptor kinases with their ligands can create localized high concentrations that enhance binding. These regulatory mechanisms ensure that kinase binding is dynamic and context-dependent.
kinase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABL1 | Chronic myeloid leukemia; imatinib resistance | Knock-in of T315I mutation in K562 cells |
| EGFR | Non-small cell lung cancer; tyrosine kinase inhibitor resistance | Point mutation (T790M) knock-in in PC9 cells |
| BRAF | Melanoma; vemurafenib resistance | Knockout of BRAF in A375 cells followed by mutant rescue |
| JAK2 | Myeloproliferative neoplasms | Knock-in of V617F mutation in Ba/F3 cells |
| PINK1 | Parkinson's disease; mitophagy | Knockout in SH-SY5Y cells and rescue with binding-deficient mutants |
Kinase binding in cancer
Dysregulated kinase binding is a hallmark of many cancers. Mutations in kinases such as ABL1, EGFR, BRAF, and ALK can alter binding affinities for ATP or substrates, leading to constitutive activation. FDA-approved small-molecule kinase inhibitors target these binding pockets, but resistance mutations often arise that reduce drug binding while preserving catalytic activity. Quantitative analysis of inhibitor selectivity has shown that the kinome-wide binding profile of a drug determines its therapeutic window and off-target effects. Therefore, characterizing kinase binding is essential for predicting clinical responses and designing next-generation inhibitors [3, 6].
Kinase binding in neurodegeneration
Kinases such as PINK1 and LRRK2 are implicated in Parkinson's disease, and their binding interactions with substrates and partners are critical for mitochondrial quality control and neuronal survival. Pseudokinases like TRIB1 can modulate signaling pathways relevant to neurodegeneration by acting as scaffolds. Understanding how these binding events are altered in disease may reveal new therapeutic opportunities.
Kinase binding in immune signaling
JAK kinases bind cytokine receptors and downstream STAT proteins, and this binding is essential for immune cell activation. JAK2 inhibitors such as ruxolitinib block these binding events and are used to treat myeloproliferative neoplasms. The FERONIA receptor kinase binds RALF peptides and undergoes phase separation to mediate global signaling in plants, illustrating conserved principles of kinase binding in cell-cell communication.
From kinase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of kinase binding affect downstream signaling? | CRISPR knockout of the kinase-binding protein followed by phospho-proteomics |
| Does a specific point mutation disrupt kinase binding? | Point-mutation knock-in of the binding interface residue |
| Can a disease-associated mutation alter kinase binding affinity? | Knock-in of the patient mutation and co-immunoprecipitation |
| Where does kinase binding occur in the cell? | Tagged knock-in of the kinase with GFP or HA for imaging |
| Does overexpression of a kinase-binding protein drive transformation? | Overexpression of the wild-type or mutant protein in primary cells |
| Can a drug disrupt kinase binding in vivo? | Xenograft models treated with small-molecule inhibitors |
How to Study the kinase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between proteins | Validation of kinase binding in cell lysates |
| Surface plasmon resonance | Binding affinity and kinetics | Characterization of inhibitor-kinase interactions |
| Isothermal titration calorimetry | Binding thermodynamics | Measuring enthalpy and stoichiometry of kinase binding |
| Phosphoproteomics | Global phosphorylation changes | Identifying downstream effects of kinase binding |
| Kinase activity assay | Catalytic activity | Distinguishing binding from phosphorylation |
| X-ray crystallography | Atomic structure of binding interface | Structure-guided design of inhibitors |
| CRISPR knockout | Loss of gene function | Testing causality of kinase binding in cells |
| Proximity ligation assay | In situ protein-protein interaction | Visualizing kinase binding in fixed cells |
Co-immunoprecipitation and pull-down assays
Co-immunoprecipitation (co-IP) is the gold-standard method to detect kinase binding in cell lysates. By immunoprecipitating the bait protein and probing for the kinase, researchers can confirm physical interaction. Pull-down assays using recombinant kinase domains or tagged baits can map binding interfaces. These methods are often combined with quantitative mass spectrometry to identify novel kinase-binding partners.
Surface plasmon resonance and isothermal titration calorimetry
Biophysical methods such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure binding affinity, kinetics, and thermodynamics. SPR can determine on-rates and off-rates for kinase-inhibitor interactions, which are critical for understanding drug selectivity. ITC provides direct measurement of binding enthalpy and stoichiometry. These techniques are essential for validating kinase binding observed in cells.
Phosphoproteomics and kinase activity assays
Phosphoproteomics using mass spectrometry can quantify changes in phosphorylation downstream of kinase binding. Kinase activity assays, such as ADP-Glo or radiometric assays, measure catalytic output. When combined with binding mutants, these methods can distinguish binding-dependent from catalysis-dependent effects.
Structural biology and computational modeling
X-ray crystallography and cryo-electron microscopy provide atomic-level views of kinase-binding interfaces. Computational docking and molecular dynamics simulations can predict how mutations or inhibitors affect binding. These approaches have been instrumental in developing conformation-tunable inhibitors and DFG-1 binders [4, 6].
How CRISPR Can Be Used to Study GO:0019900 kinase binding
Knockout
CRISPR knockout of a kinase or its binding partner can abolish the interaction and reveal its functional consequences. For example, knocking out ABL1 in cancer cell lines can test whether kinase binding is required for proliferation. Knockout models are also used to validate drug targets and to identify synthetic lethal interactions.
Point Mutation
Point mutations can be introduced to disrupt specific binding interfaces without eliminating protein expression. For instance, mutating the DFG motif or the DFG-1 residue can alter inhibitor binding while preserving catalytic activity. Point-mutation knock-in models are invaluable for studying resistance mutations and for dissecting binding versus catalysis.
Knock-in
Knock-in of tagged or mutant kinases allows precise tracking of binding events. For example, knocking in a GFP-tagged kinase enables live-cell imaging of its localization and interactions. Knock-in of disease-associated mutations, such as JAK2 V617F, can model myeloproliferative neoplasms and test targeted inhibitors.
Overexpression
Overexpression of a kinase or its binding partner can amplify signaling and reveal gain-of-function phenotypes. This approach is useful for studying oncogenic kinases and for testing whether increased binding drives transformation. Overexpression models are often combined with knockdown or knockout to confirm specificity.
How EDITGENE Supports kinase binding Research
Researchers studying kinase binding-related genes often need to determine whether a candidate gene is causally involved in a phenotype or whether its binding interface is essential for function. CRISPR-based models provide the precision required to dissect these questions, from complete knockout to single-residue point mutations and tagged knock-ins. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for kinase binding research.
Frequently Asked Questions About kinase binding
What is GO:0019900 kinase binding?
GO:0019900 is a Gene Ontology molecular function term defined as binding to a kinase, any enzyme that catalyzes the transfer of a phosphate group.
What genes are involved in kinase binding?
Genes encoding kinases such as ABL1, EGFR, BRAF, ALK, JAK2, and SRC, as well as pseudokinases like TRIB1 and STRAD, are commonly studied in kinase binding [7, 8].
How is kinase binding measured experimentally?
Common methods include co-immunoprecipitation, surface plasmon resonance, isothermal titration calorimetry, and phosphoproteomics [1, 3].
Why is kinase binding important for drug discovery?
Most small-molecule kinase inhibitors work by binding to the kinase domain, and understanding these interactions is critical for selectivity and efficacy [1, 8].
What are pseudokinases and how do they relate to kinase binding?
Pseudokinases are kinase-like proteins that lack catalytic activity but can still bind nucleotides and partner proteins, acting as scaffolds.
Can CRISPR be used to study kinase binding?
Yes, CRISPR knockout, point-mutation knock-in, and tagged knock-in models are powerful tools to dissect kinase binding interfaces and their functions.
What diseases are associated with altered kinase binding?
Cancer, neurodegenerative diseases, and immune disorders are linked to mutations that affect kinase binding.
What is the DFG-1 residue and why does it matter?
The DFG-1 residue is adjacent to the DFG motif in the kinase domain and can be targeted to develop selective inhibitors.
How does phase separation relate to kinase binding?
Phase separation can concentrate kinases and their binding partners, enhancing signaling, as shown for the FERONIA receptor kinase.
What services does EDITGENE offer for kinase binding research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
GO:0019900 kinase binding is a fundamental molecular function that underpins cellular signaling, drug action, and disease mechanisms. From ATP-competitive inhibitors to pseudokinase scaffolds, the binding of proteins to kinases shapes nearly every aspect of cell biology [1, 3, 7]. Understanding these interactions requires precise experimental models, and CRISPR-based approaches offer unmatched resolution. By leveraging knockout, point-mutation, knock-in, and overexpression strategies, researchers can dissect the causal roles of kinase-binding interfaces in health and disease.
References
- 1. Karaman MW et al.. 2008. A quantitative analysis of kinase inhibitor selectivity.. Nat Biotechnol 26(1):127-32 PMID: 18183025
- 2. Liu MJ et al.. 2024. Extracellular pectin-RALF phase separation mediates FERONIA global signaling function.. Cell 187(2):312-330.e22 PMID: 38157854
- 3. Jones LH. 2018. Small-Molecule Kinase Downregulators.. Cell Chem Biol 25(1):30-35 PMID: 29174540
- 4. Agius MP et al.. 2022. Conformation-tunable ATP-competitive kinase inhibitors.. Chem Commun (Camb) 58(21):3541-3544 PMID: 35195624
- 5. McGuinness ET et al.. 1985. NAD+ kinase--a review.. Int J Biochem 17(1):1-11 PMID: 2987053
- 6. Faber EB et al.. 2020. DFG-1 Binding: A New Residue for Developing Selective Kinase Inhibitors.. J Med Chem 63(18):10221-10223 PMID: 32915573
- 7. Hammarén HM et al.. 2015. Nucleotide-binding mechanisms in pseudokinases.. Biosci Rep 36(1):e00282 PMID: 26589967
- 8. Wu P et al.. 2015. FDA-approved small-molecule kinase inhibitors.. Trends Pharmacol Sci 36(7):422-39 PMID: 25975227
